| abstract |
A method of selecting a patient for treatment of cancer disease with a compound that inhibits a mitogen-activated protein kinase signaling pathway (hereinafter abbreviated MAPK), comprising: using a biological sample derived from a cancer patient, measure whether or not the beta-catenin contained in the biological sample has at least one type of mutation selected from the group consisting of S33Y, S33C, S33F, S37F, S37P, T41A, S45del, S45F, S45P and N287S; and selecting a patient that is detected to have the β-catenin mutation as a patient to undergo treatment of cancer disease with a compound that inhibits a MAPK signaling pathway. |